Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country

BMC Research Notes

Godwin R Constantine¹  Priyanga Ranasinghe³  Mekhala Dissanayake²  Thisara Perera²  WA Nuwan Kumara¹ 

[1] Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka;Ministry of Health Care and Nutrition, Colombo, Sri Lanka;Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

关键词: Developing country;    South Asia;    Sri Lanka;    Risk factors;    Prevalence;    Resistant hypertension;   

Others  :  1141606
DOI  :  10.1186/1756-0500-6-373

 received in 2013-03-19, accepted in 2013-09-19,  发布年份 2013

【 摘 要 】

Background

To study the prevalence and define deferential risk factors for ‘Resistant’ hypertension (RHT) in a hypertensive population of South Asian origin.

Methods

A descriptive cross-sectional study was carried out among hypertensive patients attending clinics at the Cardiology Unit, Colombo from July-October 2009. All the patients with hypertension who provided informed written consent were recruited to the study (n = 277). A pre-tested interviewer-administered questionnaire was used for data collection. A binary logistic-regression analysis was performed in all patients with ‘presence of RHT’ as the dichotomous dependent variable and other independent co-variants.

Results

Mean age was 61 ± 10.3 years and 50.2% were males. The mean of average systolic and diastolic blood pressures (BP) were 133.04 ± 12.91 mmHg and 81.07 ± 6.41 mmHg respectively. Uncontrolled BP was present in 41.1% (n = 114) of patients, of which RHT was present in 19.1% (n = 53). Uncontrolled BP were due to ‘therapeutic inertia’ in 27.8% of the study population. Those with diabetes mellitus, obesity (BMI > 27.5 kg/m²) and those who were older than 55 years were significantly higher in the RHT group than in the non-RHT group. In the binary logistic regression analysis older age (OR:1.36), longer duration of hypertension (OR:1.76), presence of diabetes mellitus (OR:1.67) and being obese (OR:1.84) were significantly associated with RHT.

Conclusion

A significant proportion of the hypertensive patients were having uncontrolled hypertension. Nearly 1/5^th of the population was suffering from RHT, which was significantly associated with the presence of obesity and diabetes mellitus. Therapeutic inertia seems to contribute significantly towards the presence of uncontrolled BP.

【 授权许可】

   
2013 Kumara et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hajjar I, Kotchen JM, Kotchen TA: Hypertension: trends in prevalence, incidence, and control. Ann Rev Pub Health 2006, 27:465-490.
• [2]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al.: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42(6):1206-1252.
• [3]Sarafidis PA: Epidemiology of resistant hypertension. J Clin Hypertension 2011, 13(7):523-528.
• [4]Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK: Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001, 38(5):1112-1117.
• [5]Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996, 27(3 Pt 2):481-490.
• [6]Miller NH, Hill M, Kottke T, Ockene IS: The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997, 95(4):1085-1090.
• [7]Balazovjech I, Hnilica P Jr: Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J Human Hypertension 1993, 7(6):581-583.
• [8]Gerber JC, Stewart DL: Prevention and control of hypertension and diabetes in an underserved population through community outreach and disease management: a plan of action. J Assoc Acad Minority Physicians 1998, 9(3):48-52.
• [9]Wienick RM, Zuvekas SH, Cohen JW: Racial and ethnic differences in access to and use of Health care services. Med Care Res Rev 2000, 57(Suppl 1):36-54.
• [10]Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282(15):1458-1465.
• [11]Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A: High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertension 2001, 19(11):2063-2070.
• [12]Wijewardene K, Mohideen MR, Mendis S, Fernando DS, Kulathilaka T, Weerasekara D, Uluwitta P: Prevalence of hypertension, diabetes and obesity: baseline findings of a population based survey in four provinces in Sri Lanka. Ceylon Med J 2005, 50(2):62-70.
• [13]Abeywardena MY: Dietary fats, carbohydrates and vascular disease: Sri Lankan perspectives. Atherosclerosis 2003, 171(2):157-161.
• [14]Bansal SK, Saxena V, Kandpal SD, Gray WK, Walker RW, Goel D: The prevalence of hypertension and hypertension risk factors in a rural Indian community: A prospective door-to-door study. J Card Disease Res 2012, 3(2):117-123.
• [15]Leenen FH, Dumais J, McInnis NH, Turton P, Stratychuk L, Nemeth K, Lum-Kwong MM, Fodor G: Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008, 178(11):1441-1449.
• [16]Kato N: Ethnic differences in genetic predisposition to hypertension. Hypertension Res 2012, 35(6):574-581.
• [17]Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 2000, 101(3):329-335.
• [18]Consultation WHOE: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363(9403):157-163.
• [19]Parascandola M, Augustson E, Rose A: Characteristics of current and recent former smokers associated with the use of new potential reduced-exposure tobacco products. J Soc Res Nicot Tobacco 2009, 11(12):1431-1438.
• [20]Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R, Third National H, Examination S: Alcohol consumption and the prevalence of the Metabolic Syndrome in the US.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diab Care 2004, 27(12):2954-2959.
• [21]Redon J, Coca A, Lazaro P, Aguilar MD, Cabanas M, Gil N, Sanchez-Zamorano MA, Aranda P: Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertension 2010, 28(8):1770-1777.
• [22]Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM: Physician-related barriers to the effective management of uncontrolled hypertension. Archives Internal Med 2002, 162(4):413-420.
• [23]Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA: Inadequate management of blood pressure in a hypertensive population. New Eng J Med 1998, 339(27):1957-1963.
• [24]Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J: Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001, 38(4):809-814.
• [25]Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003, 290(2):199-206.
• [26]Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D: Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community. Hypertension 2000, 36(4):594-599.
• [27]Haslam DW, James WP: Obesity. Lancet 2005, 366(9492):1197-1209.
• [28]Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223.
• [29]Thomas F, Bean K, Pannier B, Oppert JM, Guize L, Benetos A: Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension 2005, 46(4):654-659.
• [30]Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, et al.: Resistant hypertension: diagnosis, evaluation, and treatment. a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51(6):1403-1419.
• [31]D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008, 117(6):743-753.
• [32]Hannila-Handelberg T, Kontula K, Tikkanen I, Tikkanen T, Fyhrquist F, Helin K, Fodstad H, Piippo K, Miettinen HE, Virtamo J, et al.: Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet 2005, 6:4.
• [33]Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB: CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003, 95(3):1297-1300.
• [34]Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, et al.: Association between the CYP3A5 genotype and blood pressure. Hypertension 2005, 45(2):294-298.
• [35]Oliveira-Paula GH, Lacchini R, Coeli-Lacchini FB, Junior HM, Tanus-Santos JE: Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. Gene 2013, 25(2):391-395.
• [36]Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, et al.: CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc 2012, 1(4):e001081.
• [37]Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, Junior HM: Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol 2011, 30(8):555-564.
• [38]Santulli G, Trimarco B, Iaccarino G: G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. J Italian Soc Hypertension 2013, 20(1):5-12.
• [39]Krakoff LR: Diuretics for hypertension. Circulation 2005, 112(10):e127-129.
• [40]Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, et al.: Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005, 293(13):1595-1608.
• [41]Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J: Beta-blockers for hypertension. Cochrane Database Syst Rev 2007., 1CD002003
• [42]Santulli G: Coronary heart disease risk factors and mortality. JAMA 2012, 307(11):1137. author reply 1138